Association of vitamin D receptor gene polymorphisms with metabolic syndrome: a case–control design of population-based cross-sectional study in North China

  • Yi Zhao1,

    Affiliated with

    • Sha Liao1,

      Affiliated with

      • Jun He1,

        Affiliated with

        • Yanan Jin1,

          Affiliated with

          • Hailong Fu1,

            Affiliated with

            • Xiaoying Chen2,

              Affiliated with

              • Xuemin Fan3,

                Affiliated with

                • Hongxia Xu1,

                  Affiliated with

                  • Xiuying Liu1,

                    Affiliated with

                    • Jing Jin4 and

                      Affiliated with

                      • Yuhong Zhang1Email author

                        Affiliated with

                        Contributed equally
                        Lipids in Health and Disease201413:129

                        DOI: 10.1186/1476-511X-13-129

                        Received: 10 May 2014

                        Accepted: 5 August 2014

                        Published: 9 August 2014

                        Abstract

                        Background

                        Metabolic syndrome (MS) increases a risk of developing cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM). The Vitamin D Receptor gene (VDR) may be important for developing MS. The aim of this study is to investigate the correlation between the VDR gene polymorphisms and MS in North China.

                        Methods

                        A case–control study included 391 participants with MS according to the MS diagnostic criteria of International Diabetes Federation 2005 (IDF2005) and 400 controls was conducted on the basis of a cross sectional study which was performed from 2008 to 2012 in Ningxia Hui Autonomous Region, China. Anthropometric data, blood pressure and blood samples were collected in the field investigation. Blood biochemistry analyses were carried out in the laboratory. Two single-nucleotide polymorphisms (SNPs) in the VDR gene, BsmI (rs1544410 A > G) and FokI (rs 2228570 C > T), were genotyped.

                        Results

                        The difference in the occurrence of genotypes in BsmI between individuals with MS and the control group was significant. Compared with genotype Bb/bb and allele b, genotype BB and allele B showed higher frequencies in MS cases than controls, which suggested they were risk factors. In addition, the genotype BB carriers with MS presented a higher waist circumference, while genotype FF for the FokI polymorphism was correlated with lower BMI in subjects with MS.

                        Conclusion

                        Our study suggests that the VDR gene polymorphisms appear to be associated with MS in the Northern Chinese population. Allele B and BB genotype for BsmI are risk factors for MS. The BsmI polymorphism seems to influence waist circumference, while the FokI polymorphism influence BMI in subjects with MS.

                        Keywords

                        Vitamin D Receptor gene Polymorphisms Metabolic syndrome

                        Background

                        Metabolic syndrome (MS) includes a variety of metabolic components in abnormal pathological state, which contains abnormal plasma glucose, dyslipidemia, high blood pressure, and high cholesterol [1]. Patients with MS have a greater risk of developing cardiovascular disease (CVD) and type 2 diabetes mellitus (T2DM) [24]. For the past few years, the prevalence of MS has been on the rise in adults globally, increasing from about 20% to 40% [58] in multiple groups of people, and is becoming a serious global health burden. Although insulin resistance [9] and central obesity [10] are considered to be its primary etiological factors, genetics undoubtedly plays an important role as well. In particular, genetic influence may be different among various ethnic groups [11].

                        The Vitamin D receptor (VDR) is a member of the steroid hormone receptor family that acts as a transcriptional activator of many genes. The DNA polymorphisms that have been often reported for the VDR gene are (described in both restriction sites and dbSNP info): BsmI (rs1544410 A > G), FokI (rs 2228570 C > T), TaqI (rs731236 T > C), and ApaI (rs 7975232 C > T). In past years, many studies have found that these polymorphisms are related to bone mineral density(BMD) [12], calcium metabolism [13], tuberculosis, hepatitis [14] and cancer [15, 16]. Additionally, some of these polymorphisms have been recently identified to be associated with type 1 diabetes [17], T2DM [18], and insulin secretion [19].

                        Although the molecular mechanisms of VDR in components of MS remain unclear, a relationship between 25(OH)D3 and the disorders of MS has been previously demonstrated [2023]. Studies have also discussed VDR gene polymorphisms for associations with the components of MS, which suggest that two major VDR gene polymorphisms (BsmI and FokI) seemed to influence BMI, insulin resistance, and serum HDL cholesterol [24, 25]. However, little is known about the role of VDR gene polymorphisms in MS for Chinese population.

                        Therefore, we suppose the two single-nucleotide polymorphisms (SNPs), BsmI (rs1544410 A > G) and FokI (rs 2228570 C > T), of the VDR gene intricately affect the development of MS. This study was designed to determine the contribution of VDR polymorphisms to MS in a population from North China.

                        Materials and methods

                        Participants

                        A cross-sectional study was conducted from 2008 to 2012 in Guyuan County, Qingtongxia County and Pingluo County, of Ningxia Hui Autonomous Region, China. Stratified cluster sampling was applied to select two villages (one Hui ethnic village and one Han ethnic village) in each county, totaling six villages. During the study period, 4614 subjects aged 24–75 were interviewed with a questionnaire, followed by anthropometric measurements (height, weight, waist circumference), and blood pressure determination. Pregnant or breastfeeding women, patients with severe mental disease and other serious illness were excluded from the study. The subjects enrolled did not report to have chronic viral infection, cold or flu, acute respiratory infection, or any type of surgery in the week preceding the study. Meanwhile, 2615 participants had blood drawn via venipuncture for laboratory measurements, and finally 1169 blood samples were selected for genotyping by mechanical sampling (k = 1). Based on diagnostic criteria (International Diabetes Federation IDF-2005), 391 cases with MS and 400 controls were selected from the same population to conduct the case–control study. The study protocol had been approved by the Medical Ethics Review Committee of Ningxia Medical University. All participants signed the consents on enrollment after they received written and verbal information about the study.

                        All participants were interviewed by trained persons with a standard closed-ended questionnaire. The contents of the questionnaire included general demographic characteristics, blood pressure, blood lipid, blood sugar, smoking, physical activity status, drinking and related diseases (including hypertension, coronary heart disease, stroke and diabetes medical history and family history, individual treatment, etc.).

                        Anthropometric measurements and blood pressure

                        Standing height was measured using a portable ruler. Body weight was also measured using a weight scale (Omron, China). All measurements were performed by well-trained investigators. The reading of measurements was accurate within 0.1 cm or 0.1 kg, and the average of the two collected measures was recorded for further analysis. Body mass index (BMI) was calculated as kg/m2. Obesity was defined as BMI ≥ 30. Arterial blood pressure was measured three times in sitting position using an electronic sphygmomanometer (Omron-HEM 7301-IT, China). All participants were at rest for at least 30 minutes before the measurement was collected. Patients with average blood pressures ≥140/90 mmHg or taking antihypertensive medication in 2 weeks were classified as being hypertensive.

                        Blood biochemistry analyses

                        Blood samples were drawn from the antecubital vein at the hours of 6 to 8 AM, after at least 10 hours of fasting and avoidance of alcohol. Two sets of fasting blood samples were collected separately from each subject in sodium fluoride potassium oxalate tubes (for glucose) and lithium heparin vacuum tubes (for lipids). The latter collections were then centrifuged and kept at −80°C until analysis. Fasting glucose was immediately determined by One Touch Ultra 2 (LifeScan, USA). Serum levels of HDL- cholesterol, LDL- cholesterol, and triglycerides were measured by enzymatic assay (CHOD-PAP, Roche Diagnostics GmbH). All analyses were carried out through an automatic biochemical analyzer (COBASE 501, Roche Diagnostics GmbH). Subjects were further divided into two groups, cases with MS and controls without MS, according to the IDF definition. For a subject to be defined as having MS, they must have: Central obesity (waist circumference ≥ 90 cm in males, ≥ 80 cm in females, or BMI is >30 kg/m2) along with any two of the following four factors: triglycerides ≥ 150 mg/dL (1.7 mmol/L); HDL-cholesterol < 40 mg/dl (1.03 mmol/L) in males, < 50 mg/dL(1.29 mmol/L) in females; blood pressure, systolic BP ≥ 130 or diastolic BP ≥ 85 mmHg; fasting glucose ≥5.6 mmol/L (100 mg/dl) [1].

                        Genotyping

                        Genomic DNA was extracted from the whole blood with the SE Blood DNA Kit (OMEGA, USA). After extraction, 30 samples of the extracted material were randomly selected for validation by agarose gel electrophoresis. SNP genotyping of BsmI and FokI in the VDR gene was performed using a technology known as SNPscan™ [2628](Genesky Biotechnologies, China). SNPscan™ is a patent technology and developed on double ligation and multiplex fluorescence PCR with high genotyping accuracy (>99.9%) and call rate (>98%). Specifically, highly multiple ligation products in different length were generated on account of high specificity of the ligase reaction. Meanwhile, the ligation probes and templates were further lengthened through double ligation. With blue fluorescent dye modified universal primers, ligation products were amplified by Thermal Cycler (ABI, USA) and then detected through fluorescent capillary electrophoresis. Finally, GeneMapper (Life Technologies) software was used to read the data.

                        Statistical analysis

                        Statistical analysis was conducted using SPSS statistical software (version 14.0 SPSS Corp, College Station, TX) and descriptive data were presented by mean and standard deviation. The Kolmogorov-Smirnov test was used to analyze normality of the distribution of each variable. Comparisons between any two groups were performed using independent t-tests. Chi-square analysis was applied to examine the variation of sex, genotype and gene frequency in different MS groups. Chi-square analysis was also used to test Hardy–Weinberg equilibrium (HWE) for the genotypes in all groups of subjects. ANOVA analysis was used to analyze clinical variables in different genotypes. Odds ratios (ORs) and their 95% confidence interval (CI) were computed for the risk alleles from logistic regression analysis. Statistical significance was set at P < 0.05.

                        Results

                        General characteristics and components of MS

                        Characteristics of the subjects with and without MS are shown in Table 1. In our study, the mean age of the 391 participants with MS was 53 (±11) years, and the mean age of 400 controls was 53 (±11) years. Compared with the controls, BMI, waist circumference, blood pressure, fasting glucose, and triglycerides were significantly higher in individuals with MS, while HDL cholesterol was lower. Both VDR BsmI and FokI genotypic distributions in controls were in Hardy-Weinberg equilibrium (P, 0.762 and 0.376, respectively) (Table 2).
                        Table 1

                        Population Characteristics and components of MS

                         

                        MS

                        Control

                        P-value

                        Male/Female, n

                        99/292

                        100/300

                        0.917

                        Age

                        53.37 ± 10.99

                        53.73 ± 11.08

                        0.997

                        Height(cm)

                        159.09 ± 8.11

                        157.73 ± 7.34

                        0.018

                        Weight(kg)

                        66.19 ± 10.15

                        56.09 ± 7.90

                        <0.001

                        BMI

                        26.09 ± 2.97

                        22.53 ± 2.72

                        <0.001

                        WC(cm)

                        89.70 ± 6.63

                        79.11 ± 7.47

                        <0.001

                        BPS(mmHg)

                        136.88 ± 20.38

                        124.87 ± 18.29

                        <0.001

                        BPD(mmHg)

                        84.13 ± 11.55

                        77.19 ± 11.01

                        <0.001

                        FBG(mmol/L)

                        6.15 ± 1.31

                        5.58 ± 0.83

                        <0.001

                        TG(mmol/L)

                        2.07 ± 1.19

                        1.30 ± 1.16

                        <0.001

                        HDL-C(mmol/L)

                        1.28 ± 0.38

                        1.48 ± 0.34

                        <0.001

                        WC, Waist circumference; BPS, Systolic blood pressure; BPD, Diastolic blood pressure; FBG, fasting blood-glucose; TG, triglycerides; HDL-C, HDL- cholesterol.

                        Table 2

                        Hardy-Weinberg equilibrium of control group

                        Genotype

                        Predictive value

                        Observed value

                        χ2

                        P-value

                        BsmI

                        CC

                        328.52

                        328

                        0.092

                        0.762

                        CT

                        67.97

                        69

                        TT

                        3.52

                        3

                        FokI

                        AA

                        84.39

                        80

                        0.783

                        0.376

                        AG

                        198.22

                        207

                         

                        GG

                        116.39

                        112

                          

                        The distribution of VDR BsmI and FokI polymorphisms

                        As shown in Table 3, both genotypic and allelic frequencies of VDR BsmI and FokI polymorphisms were presented for participants with or without MS. Genotypes of BsmI and FokI are normally expressed as dominant homozygous genotype “BB, FF”, heterozygous genotype “Bb, Ff”, and recessive homozygous genotype “bb, ff”. There were differences in genotypes and gene frequencies of VDR BsmI between the MS cases and controls, with P-values of 0.011 and 0.03 respectively. Frequency of genotype BB and Bb was significantly different between individuals with MS and without MS, after comparing all of the three genotypes with each other (χ 2 = 7.022, P = 0.008). However, there was no difference in FokI polymorphism.
                        Table 3

                        Genotypes and gene frequencies

                         

                        BsmI

                        FokI

                         

                        BB

                        Bb

                        bb

                        B

                        b

                        FF

                        Ff

                        ff

                        F

                        f

                        MS, n

                        347

                        42

                        1

                        736

                        44

                        75

                        184

                        132

                        334

                        448

                        Control, n

                        328

                        69

                        3

                        725

                        75

                        80

                        207

                        112

                        367

                        431

                        χ 2

                        --

                        9.016

                        3.073

                        1.720

                        P -value

                        0.011*

                        0.03

                        0.215

                        0.19

                        *Fisher's Exact Test; BB/FF normally show dominant homozygous genotype; Bb/Ff show heterozygous genotype; bb/ff show recessive homozygous genotype.

                        VDR polymorphisms and MS risk

                        The difference in the occurrence of the genotypes in BsmI between individuals with MS and the control group was significant (P trend = 0.02). The frequencies of genotype BB and combined Bb/bb in individuals with MS were 89% and 11% respectively, in the control group were 82% and 18% respectively, which suggested that the genotype BB was a risk factor (P = 0.006; OR = 1.771; 95% CI, 1.179-2.661). Compared with genotype BB, genotype Bb was likely to be a protective factor (P = 0.009; OR = 0.575; 95% CI, 0.381-0.869). The incidences of B and b alleles for the BsmI polymorphism in the two group were statistically significant (allele B vs. b; P = 0.005), which indicated allele b could be a protective factor. However, it seemed no significant evidence to be risk factors or protective factors to FokI polymorphism in individuals with MS (Table 4).
                        Table 4

                        FokI and BsmI polymorphisms and MS risk

                        Genotype

                        MS n(%)

                        Control n(%)

                        P-value

                        OR

                        95% CI

                        BsmIa

                             

                        BB(CC)

                        347(89.0)

                        328(82.0)

                         

                        1

                         

                        Bb(CT)

                        42(10.7)

                        69(17.3)

                        0.009

                        0.575

                        0.381-0.869

                        bb(TT)

                        1(0.3)

                        3(0.7)

                        0.318

                        0.315

                        0.033-3.044

                        Bb + bb

                        43

                        72

                         

                        1

                         

                        BB

                        347

                        328

                        0.006

                        1.771

                        1.179-2.661

                        B

                        736(94.4)

                        725(90.6)

                         

                        1

                         

                        b

                        44(5.6)

                        75(9.4)

                        0.005

                        0.578

                        0.393-0.850

                        FokIb

                             

                        FF(AA)

                        75(19.2)

                        80(20.0)

                         

                        1

                         

                        Ff(AG)

                        184(47.1)

                        207(58.9)

                        0.779

                        0.948

                        0.653-1.376

                        ff(GG)

                        132(33.7)

                        112(28.1)

                        0.266

                        1.257

                        0.840-1.882

                        Ff + ff

                        316

                        319

                         

                        1

                         

                        FF

                        75

                        80

                        0.759

                        0.946

                        0.666-1.345

                        F

                        334(42.7)

                        367(46.0)

                         

                        1

                         

                        f

                        448(57.3)

                        431(54.0)

                        0.190

                        1.142

                        0.936-1.393

                        BBFFc

                        69

                        68

                         

                        1

                         

                        BBFf

                        164

                        174

                        0.761

                        0.929

                        0.624-1.382

                        BBff

                        114

                        85

                        0.211

                        1.322

                        0.854-2.046

                        BbFF

                        5

                        11

                        0.156

                        0.448

                        0.148-1.358

                        BbFf

                        19

                        32

                        0.111

                        0.585

                        0.303-1.131

                        Bbff

                        18

                        26

                        0.276

                        0.682

                        0.343-1.358

                        bbFF

                        0

                        1

                        1.000

                        0.000

                        0.000

                        bbFf

                        1

                        1

                        0.992

                        0.986

                        0.060-16.077

                        Bbff

                        0

                        1

                        1.000

                        0.000

                        0.000

                        aP trend = 0.02; bP trend = 0.216; cP trend = 0.187;BB/FF normally show dominant homozygous genotype; Bb/Ff show heterozygous genotype; bb/ff show recessive homozygous genotype.

                        Moreover, the genotypes of BsmI and FokI were combined and generated as 9 new genotypes like BBFF to analyze the cumulative effect of the polymorphisms, as shown in Table 4. But there were no significant differences in the risk of MS (P trend = 0.187).

                        The associations of VDR gene polymorphisms with the components of MS

                        Table 5 presented the distribution of some clinical variables according to the genotypes observed in individuals with MS and without MS. Because of the limited frequencies of genotype bb in the VDR BsmI polymorphism, we combined Bb and bb genotype as a group. For the VDR BsmI variant, individuals with MS carrying BB genotype presented a higher waist circumference than individuals with Bb + bb genotype, whilst genotype BB was associated with higher waist circumference and BMI in individuals without MS than seen in others. Additionally, the presence of FF genotype for the FokI polymorphism was associated with lower BMI than that with Ff/ff genotype in individuals with MS. In addition, to the individuals without MS, higher systolic blood pressure was seen in subjects with Ff genotype than that with ff genotype, and subjects with genotype FF/Ff presented a higher diastolic blood pressure than individuals with ff genotype. Moreover, the values of the remaining variables were very similar among all subjects for both VDR BsmI and FokI polymorphisms.
                        Table 5

                        FokI and BsmI polymorphisms and MS components

                         

                        BsmI(rs1544410 A > G)

                        P

                        FokI(rs 2228570 C > T)

                        P

                         

                        BB

                        Bb + bb

                         

                        FF

                        Ff

                        ff

                         

                        MS

                        BMI

                        26.1 ± 3.1

                        25.7 ± 2.2

                        0.396

                        25.1 ± 2.5a

                        26.3 ± 3.1

                        26.4 ± 2.9

                        0.005

                         WC(cm)

                        90 ± 6.6

                        87.6 ± 6.3

                        0.025

                        88.7 ± 5.5

                        89.7 ± 7

                        90 ± 6.6

                        0.284

                        BPS(mmHg)

                        136.4 ± 19.8

                        141.9 ± 22.7

                        0.096

                        135.9 ± 20

                        137.5 ± 20.6

                        136.6 ± 20.4

                        0.829

                        BPD(mmHg)

                        84.1 ± 11.4

                        85 ± 12.5

                        0.625

                        84 ± 11.8

                        84.8 ± 11.3

                        83.2 ± 11.8

                        0.438

                        FBG(mmol/L)

                        6.1 ± 1.2

                        6.4 ± 2.2

                        0.163

                        6.2 ± 1.6

                        6.1 ± 1

                        6.2 ± 1.5

                        0.496

                        TG(mmol/L)

                        2.1 ± 1.2

                        2 ± 1.2

                        0.788

                        2.1 ± 0.9

                        2.1 ± 1.3

                        2 ± 1.2

                        0.821

                        HDL-C(mmol/L)

                        1.3 ± 0.4

                        1.4 ± 0.3

                        0.177

                        1.2 ± 0.3

                        1.3 ± 0.3

                        1.3 ± 0.5

                        0.077

                        Control

                        BMI

                        22.7 ± 2.8

                        22 ± 2.4

                        0.030

                        22.5 ± 2.9

                        22.5 ± 2.6

                        22.5 ± 2.8

                        0.995

                        WC(cm)

                        79.7 ± 7.6

                        76.3 ± 6.1

                        0.000

                        78.7 ± 8

                        79.2 ± 6.5

                        79.2 ± 8.7

                        0.849

                        BPS(mmHg)

                        124.9 ± 18.3

                        124.9 ± 18.3

                        0.985

                        124.9 ± 18.6

                        126.8 ± 19.3b

                        121.5 ± 15.6

                        0.045

                        BPD(mmHg)

                        77.2 ± 11.1

                        77.1 ± 10.8

                        0.939

                        78.2 ± 10.5

                        78.1 ± 11.8

                        74.9 ± 9.4a

                        0.031

                        FBG(mmol/L)

                        5.6 ± 0.9

                        5.6 ± 0.5

                        0.727

                        5.5 ± 0.8

                        5.7 ± 1

                        5.5 ± 0.5

                        0.118

                        TG(mmol/L)

                        1.3 ± 1.2

                        1.2 ± 0.6

                        0.254

                        1.3 ± 0.6

                        1.3 ± 1.5

                        1.2 ± 0.6

                        0.789

                        HDL-C(mmol/L)

                        1.5 ± 0.3

                        1.5 ± 0.3

                        0.227

                        1.4 ± 0.3

                        1.5 ± 0.3

                        1.5 ± 0.3

                        0.596

                        asignificant for the genotype Ff/ff; bsignificant for the genotype ff.

                        Discussion

                        The results showed that VDR polymorphisms may influence the emergence of MS. The VDR BsmI (rs1544410 A > G) polymorphism appeared to associate with MS. Specifically, allele B and genotype of BB in BsmI were associated with MS, while allele b and genotype Bb seemed to play a protective role. The role of genotype bb was unclear, because of its limited frequency. When discussed VDR gene polymorphisms with the components of MS, we found the genotype BB carriers with MS presented a higher waist circumference. In addition, genotype FF for the VDR FokI (rs2228570 C > T) polymorphism was correlated with lower BMI in MS. Our findings were different with previous researches which demonstrated the VDR FokI polymorphism was related with triglycerides and HDL-cholesterol levels [25].

                        A few studies have demonstrated that VDR polymorphisms were related to obesity, diabetes, insulin sensitivity and insulin secretion [17, 19, 29]. VDR BsmI and FokI polymorphisms have been previously reported to be associated with anthropometric and biochemical parameters describing MS. Trzmiel et al. (2008) found that VDR BsmI polymorphism seemed to influence BMI, while the FokI VDR polymorphism appeared to affect insulin sensitivity and serum HDL cholesterol in men [24]. However, Lwow et al. (2008) indicated that VDR BsmI polymorphism did not seem to predispose postmenopausal women to obesity and insulin resistance, but the genotype BB was connected with dyslipidemia [30]. Frey et al. (2003) did not find evidence for the association of VDR polymorphisms with glycemia either [31]. Results of these study seemed to conflict with the pleiotropic effect of the VDR gene in individuals with MS, and this result was not found in other populations [32]. Moreover, interactions in circulating glucose, triglyceride, cholesterol and insulin levels were not well explained [33, 34]. For this reason, whether these differences come from ethnic variations or interactions in components of MS still needs further exploration, and we should not focus on the disorders in MS separately.

                        The VDR gene is not a main influencing factor to the variability of circulating levels of vitamin D, according to genome-wide association (GWA) studies [17, 35, 36]. However, it is clear that the VDR gene plays a primary role in the pleiotropic actions of 1,25(OH)2D3[37] and in insulin secretion [19, 38]. Serum 25-hydroxyvitamin D levels is inversely related to percentage body fat content in healthy women [20] and incident hypertension [21]. Furthermore, McKeown et al. (2011) found that the predicted 25-hydroxyvitamin D score might be an important determinant for change in fasting plasma glucose concentration in the Framingham offspring study [22]. Unfortunately, our study did not include serum 25-hydroxyvitamin D, but we could assume that serum 25-hydroxyvitamin D is the focus leading metabolic disorders if the interactions we discussed above were taken into consideration.

                        Conclusion

                        This study revealed a significant association of VDR BsmI polymorphism with MS in the Northern Chinese population. Allele B and genotype BB for BsmI are risk factors for MS. The BsmI polymorphism seemed to influence waist circumference, while the FokI polymorphism influence BMI in subjects with MS. Thus, we propose that the BsmI and FokI polymorphisms of VDR are potential prognostic variables which may predict the risk of developing MS. Even so, further examination should be carried out on large population. Also, genome wide association studies are still needed to evaluate the direct effect of these polymorphisms on MS.

                        Authors’ information

                        Yi Zhao and Sha Liao Co-first authors.

                        Notes

                        Abbreviations

                        MS: 

                        Metabolic syndrome

                        VDR: 

                        Vitamin D Receptor gene

                        CVD: 

                        Cardiovascular disease

                        T2DM: 

                        Type 2 diabetes mellitus

                        IDF2005: 

                        International Diabetes Federation 2005

                        SNPs: 

                        Single-nucleotide polymorphisms

                        BMD: 

                        Bone mineral density

                        BMI: 

                        Body mass index

                        WC: 

                        Waist circumference

                        BPS: 

                        Systolic blood pressure

                        BPD: 

                        Diastolic blood pressure

                        FBG: 

                        Fasting blood-glucose

                        TG: 

                        Triglycerides

                        HWE: 

                        Hardy–Weinberg equilibrium

                        CI: 

                        Confidence interval

                        GWA: 

                        Genome-wide association.

                        Declarations

                        Acknowledgements

                        This study was supported by Natural Science Foundation of China (No.81160358). The authors wish to thank: doctors of each Rural Hospital for their administrative support during the performing stage of the study and all interviewees who agreed to participate in the study.

                        Authors’ Affiliations

                        (1)
                        School of Public Health, Ningxia Medical University
                        (2)
                        Centers for Disease Control and Prevention in Ningxia
                        (3)
                        Department of Clinic Administrations, Ningxia People’s Hospital
                        (4)
                        Affiliated Hospital of Ningxia Medical University

                        References

                        1. Alberti KGM, Zimmet P, Shaw J: The metabolic syndrome—a new worldwide definition[J]. Lancet. 2005, 366 (9491): 1059-1062.View ArticlePubMed
                        2. Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence[J]. Diabetes Care. 2005, 28 (7): 1769-1778.View ArticlePubMed
                        3. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM: Metabolic syndrome and risk of incident cardiovascular events and DeathA systematic review and meta-analysis of longitudinal studies[J]. J Am Coll Cardiol. 2007, 49 (4): 403-414.View ArticlePubMed
                        4. Wilson PWF, D’Agostino RB, Parise H, Sullivan L, Meigs JB: Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus[J]. Circulation. 2005, 112 (20): 3066-3072.View ArticlePubMed
                        5. Ford ES, Giles WH, Dietz WH: Prevalence of the metabolic syndrome among us adults: Findings from the third national health and nutrition examination survey[J]. JAMA. 2002, 287 (3): 356-359.View ArticlePubMed
                        6. Gu D, Reynolds K, Wu X, Chen J, Duan X, Reynolds RF, Whelton PK, He J: Prevalence of the metabolic syndrome and overweight among adults in China[J]. Lancet. 2005, 365 (9468): 1398-1405.View ArticlePubMed
                        7. Ramli AS, Daher AM, Nor Ashikin MN, Mat Nasir N, Ng KK, Miskan M, Ambigga KS, Ariffin F, Mazapuspavina MY, Abdul Razak S, Abdul Hamid H, Abd Majid F, Abu Bakar N, Nawawi H, Yusoff K: JIS definition identified more Malaysian adults with metabolic syndrome compared to the NCEP-ATP III and IDF criteria[J]. Biomed Res Int. 2013, 2013: 760963-PubMed CentralView ArticlePubMed
                        8. Yi Z, Jing J, Xiuying L, Hongxia X, Jianjun Y, Yuhong Z: Prevalence of the metabolic syndrome among rural original adults in NingXia, china[J]. BMC Public Health. 2010, 10 (1): 140-PubMed CentralView ArticlePubMed
                        9. Hu G, Qiao Q, Tuomilehto J, Eliasson M, Feskens EJ, Pyörälä K: Plasma insulin and cardiovascular mortality in non-diabetic European men and women: a meta-analysis of data from eleven prospective studies[J]. Diabetologia. 2004, 47 (7): 1245-PubMed
                        10. Després J-P, Lemieux I: Abdominal obesity and metabolic syndrome[J]. Nature. 2006, 444 (7121): 881-887.View ArticlePubMed
                        11. Oh J-Y, Barrett-Connor E: Association between vitamin D receptor polymorphism and type 2 diabetes or metabolic syndrome in community-dwelling older adults: the rancho Bernardo study[J]. Metab Clin Exp. 2002, 51 (3): 356-359.View ArticlePubMed
                        12. Cooper GS, Umbach DM: Are vitamin D receptor polymorphisms associated with bone mineral density? A meta‒analysis[J]. J Bone Miner Res. 1996, 11 (12): 1841-1849.View ArticlePubMed
                        13. Li YC, Bolt MJ, Cao LP, Sitrin MD: Effects of vitamin D receptor inactivation on the expression of calbindins and calcium metabolism[J]. Am J Physiol-Endocrinol Metabolism. 2001, 281 (3): E558-E564.
                        14. Bellamy R, Ruwende C, Corrah T, McAdam KP, Thursz M, Whittle HC, Hill AV: Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene[J]. J Infect Dis. 1999, 179 (3): 721-724.View ArticlePubMed
                        15. John EM, Schwartz GG, Koo J, Van Den Berg D, Ingles SA: Sun exposure, vitamin D receptor gene polymorphisms, and risk of advanced prostate cancer[J]. Cancer Res. 2005, 65 (12): 5470-5479.View ArticlePubMed
                        16. Li L, Wu B, Yang L, Yin G, Wei W, Sui S, Liu J: Association of vitamin D receptor gene polymorphisms with pancreatic cancer: A pilot study in a North China Population[J]. Oncol Lett. 2013, 5 (5): 1731-1735.PubMed CentralPubMed
                        17. Cooper JD, Smyth DJ, Walker NM, Stevens H, Burren OS, Wallace C, Greissl C, Ramos-Lopez E, Hyppönen E, Dunger DB, Spector TD, Ouwehand WH, Wang TJ, Badenhoop K, Todd JA: Inherited variation in vitamin D genes is associated with predisposition to autoimmune disease type 1 diabetes[J]. Diabetes. 2011, 60 (5): 1624-1631.PubMed CentralView ArticlePubMed
                        18. Li L, Wu B, Liu JY, Yang LB: Vitamin D Receptor Gene Polymorphisms and Type 2 Diabetes: A Meta-analysis[J]. Arch Med Res. 2013, 44 (3): 235-241.View ArticlePubMed
                        19. Hitman GA, Mannan N, McDermott MF, Aganna E, Ogunkolade BW, Hales CN, Boucher BJ: Vitamin D receptor gene polymorphisms influence insulin secretion in Bangladeshi Asians[J]. DIABETES-NEW YORK. 1998, 47: 688-690.
                        20. Arunabh S, Pollack S, Yeh J, Aloia JF: Body fat content and 25-hydroxyvitamin D levels in healthy women[J]. J Clin Endocrinol Metab. 2003, 88 (1): 157-161.View ArticlePubMed
                        21. Forman JP, Giovannucci E, Holmes MD, Bischoff-Ferrari HA, Tworoger SS, Willett WC, Curhan GC: Plasma 25-hydroxyvitamin D levels and risk of incident hypertension[J]. Hypertension. 2007, 49 (5): 1063-1069.View ArticlePubMed
                        22. Liu E, McKeown N, Pittas AG, Meigs JB, Economos CD, Booth SL, Jacques PF: Predicted 25-hydroxyvitamin D score and change in fasting plasma glucose in the Framingham offspring study[J]. Eur J Clin Nutr. 2011, 66 (1): 139-141.PubMed CentralView ArticlePubMed
                        23. Liu E, Meigs JB, Pittas AG, Economos CD, McKeown NM, Booth SL, Jacques PF: Predicted 25-hydroxyvitamin D score and incident type 2 diabetes in the Framingham Offspring Study[J]. Am J Clin Nutr. 2010, 91 (6): 1627-1633.PubMed CentralView ArticlePubMed
                        24. Filus A, Trzmiel A, Kuliczkowska-Plaksej J, Tworowska U, Jedrzejuk D, Milewicz A, Medraś M: Relationship between vitamin D receptor BsmI and FokI polymorphisms and anthropometric and biochemical parameters describing metabolic syndrome[J]. Aging Male. 2008, 11 (3): 134-139.View ArticlePubMed
                        25. Schuch NJ, Garcia VC, Vivolo SR, Martini LA: Relationship between Vitamin D Receptor gene polymorphisms and the components of metabolic syndrome[J]. Nutr J. 2013, 12: 96-PubMed CentralView ArticlePubMed
                        26. Asian PJ: B-cell lymphoma 2 rs17757541 C > G polymorphism was associated with an increased risk of gastric cardiac adenocarcinoma in a Chinese population[J]. Asian Pacific J Cancer Prev. 2013, 14 (7): 4301-4306.View Article
                        27. Tanaka T, Ngwa JS, van Rooij FJ, Zillikens MC, Wojczynski MK, Frazier-Wood AC, Houston DK, Kanoni S, Lemaitre RN, Luan J, Mikkilä V, Renstrom F, Sonestedt E, Zhao JH, Chu AY, Qi L, Chasman DI, de Oliveira Otto MC, Dhurandhar EJ, Feitosa MF, Johansson I, Khaw KT, Lohman KK, Manichaikul A, McKeown NM, Mozaffarian D, Singleton A, Stirrups K, Viikari J, Ye Z: Genome-wide meta-analysis of observational studies shows common genetic variants associated with macronutrient intake[J]. Am J Clin Nutr. 2013, 97 (6): 1395-1402.PubMed CentralView ArticlePubMed
                        28. Zhang YH, Xu Q, Zhao Z, Wu J, Liu WX, Wang H, Jin L, Wang JC: Polymorphism rs7214723 in CAMKK1 and lung cancer risk in Chinese population[J]. Tumor Biol. 2013, 1-6.
                        29. Ye W-Z, Reis AF, Dubois-Laforgue D, Bellanné-Chantelot C, Timsit J, Velho G: Vitamin D receptor gene polymorphisms are associated with obesity in type 2 diabetic subjects with early age of onset[J]. Eur J Endocrinol. 2001, 145 (2): 181-186.View ArticlePubMed
                        30. Tworowska-Bardzinska U, Lwow F, Kubicka E, Łaczmański Ł, Jedzrzejuk D, Dunajska K, Milewicz A: The vitamin D receptor gene Bsm I polymorphism is not associated with anthropometric and biochemical parameters describing metabolic syndrome in postmenopausal women[J]. Gynecol Endocrinol. 2008, 24 (9): 514-518.View ArticlePubMed
                        31. Malecki M, Frey J, Moczulski D, Klupa T, Kozek E, Sieradzki J: Vitamin D receptor gene polymorphisms and association with type 2 diabetes mellitus in a Polish population[J]. Exp Clin Endocrinol Diab. 2003, 111 (08): 505-509.View Article
                        32. Valdivielso JM, Fernandez E: Vitamin D receptor polymorphisms and diseases[J]. Clin Chim Acta. 2006, 371 (1): 1-12.View ArticlePubMed
                        33. Laakso M, Sarlund H, Mykkänen L: Insulin resistance is associated with lipid and lipoprotein abnormalities in subjects with varying degrees of glucose tolerance[J]. Arterioscler Thromb Vasc Biol. 1990, 10 (2): 223-231.View Article
                        34. West KM, Ahuja M, Bennett PH, Czyzyk A, De Acosta OM, Fuller JH, Grab B, Grabauskas V, Jarrett RJ, Kosaka K: The role of circulating glucose and triglyceride concentrations and their interactions with other ―risk factors― as determinants of arterial disease in nine diabetic population samples from the WHO multinational study[J]. Diabetes Care. 1983, 6 (4): 361-369.View ArticlePubMed
                        35. Wang TJ, Zhang F, Richards JB, Kestenbaum B, van Meurs JB, Berry D, Kiel DP, Streeten EA, Ohlsson C, Koller DL, Peltonen L, Cooper JD, O'Reilly PF, Houston DK, Glazer NL, Vandenput L, Peacock M, Shi J, Rivadeneira F, McCarthy MI, Anneli P, de Boer IH, Mangino M, Kato B, Smyth DJ, Booth SL, Jacques PF, Burke GL, Goodarzi M, Cheung CL: Common genetic determinants of vitamin D insufficiency: a genome-wide association study[J]. Lancet. 2010, 376 (9736): 180-188.PubMed CentralView ArticlePubMed
                        36. Ahn J, Yu K, Stolzenberg-Solomon R, Simon KC, McCullough ML, Gallicchio L, Jacobs EJ, Ascherio A, Helzlsouer K, Jacobs KB, Li Q, Weinstein SJ, Purdue M, Virtamo J, Horst R, Wheeler W, Chanock S, Hunter DJ, Hayes RB, Kraft P, Albanes D: Genome-wide association study of circulating vitamin D levels[J]. Hum Mol Genet. 2010, 19 (13): 2739-2745.PubMed CentralView ArticlePubMed
                        37. Goltzman D: Vitamin D, action[J]. Ann N Y Acad Sci. 2010, 1192 (1): 145-152.View ArticlePubMed
                        38. Zeitz U, Weber K, Soegiarto DW, Wolf E, Balling R, Erben RG: Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor[J]. FASEB J. 2003, 17 (3): 509-511.PubMed

                        Copyright

                        © Zhao et al.; licensee BioMed Central Ltd. 2014

                        This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.

                        Advertisement